172 related articles for article (PubMed ID: 10537441)
1. A prospective evaluation of the cost effectiveness of adding lamivudine to zidovudine-containing antiretroviral treatment regimens in HIV infection. European perspective.
Lacey L; Youle M; Trueman P; Staszewski S; Schrappe M; Behrens M
Pharmacoeconomics; 1999; 15 Suppl 1():39-53. PubMed ID: 10537441
[TBL] [Abstract][Full Text] [Related]
2. An evaluation of the cost effectiveness of adding lamivudine to zidovudine-containing regimens in HIV infection. Canadian perspective.
Lacey L; Hopkinson PK; Montaner J; Leblanc F; Gill MJ
Pharmacoeconomics; 1999; 15 Suppl 1():55-66. PubMed ID: 10537442
[TBL] [Abstract][Full Text] [Related]
3. A prospective cost-consequence analysis of adding lamivudine to zidovudine-containing antiretroviral treatment regimens for HIV infection in the US.
Lacey L; Mauskopf J; Lindrooth R; Pham S; Saag M; Sawyer W
Pharmacoeconomics; 1999; 15 Suppl 1():23-37. PubMed ID: 10537440
[TBL] [Abstract][Full Text] [Related]
4. Lamivudine reduces healthcare resource use when added to zidovudine-containing regimens in patients with HIV infection.
Lacey L; Gill MJ
Pharmacoeconomics; 1999; 15 Suppl 1():13-22. PubMed ID: 10537439
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.
Sánchez-de la Rosa R; Herrera L; Moreno S
Clin Ther; 2008 Feb; 30(2):372-81. PubMed ID: 18343275
[TBL] [Abstract][Full Text] [Related]
6. The cost-effectiveness of treatment with lamivudine and zidovudine compared with zidovudine alone: a comparison of Markov model and trial data estimates.
Mauskopf J; Lacey L; Kempel A; Simpson K
Am J Manag Care; 1998 Jul; 4(7):1004-12. PubMed ID: 10181990
[TBL] [Abstract][Full Text] [Related]
7. Modelling the cost effectiveness of lamivudine/zidovudine combination therapy in HIV infection.
Chancellor JV; Hill AM; Sabin CA; Simpson KN; Youle M
Pharmacoeconomics; 1997 Jul; 12(1):54-66. PubMed ID: 10169387
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States.
Brogan AJ; Talbird SE; Cohen C
Value Health; 2011; 14(5):657-64. PubMed ID: 21839403
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of antiviral drug therapy to reduce mother-to-child HIV transmission in sub-Saharan Africa.
Marseille E; Kahn JG; Saba J
AIDS; 1998 May; 12(8):939-48. PubMed ID: 9631148
[TBL] [Abstract][Full Text] [Related]
10. Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: application to a clinical trial.
Cook J; Dasbach E; Coplan P; Markson L; Yin D; Meibohm A; Nguyen BY; Chodakewitz J; Mellors J
AIDS Res Hum Retroviruses; 1999 Apr; 15(6):499-508. PubMed ID: 10221527
[TBL] [Abstract][Full Text] [Related]
11. Quality of life and treatment satisfaction after the addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens in treatment-experienced patients with HIV infection.
Chatterton ML; Scott-Lennox J; Wu AW; Scott J
Pharmacoeconomics; 1999; 15 Suppl 1():67-74. PubMed ID: 10537443
[TBL] [Abstract][Full Text] [Related]
12. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial.
Lancet; 1997 May; 349(9063):1413-21. PubMed ID: 9164314
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV.
Pinkerton SD; Holtgrave DR; Pinkerton HJ
Arch Intern Med; 1997 Sep; 157(17):1972-80. PubMed ID: 9308509
[TBL] [Abstract][Full Text] [Related]
14. The financial and service implications of splitting fixed-dose antiretroviral drugs - a case study.
Taylor R; Carlin E; Sadique Z; Ahmed I; Adams EJ
Int J STD AIDS; 2015 Feb; 26(2):75-80. PubMed ID: 24700200
[TBL] [Abstract][Full Text] [Related]
15. Changing cost of English HIV service provision 1996-1997. NPMS Steering Group. National Prospective Monitoring System.
Int J STD AIDS; 1999 Jun; 10(6):357-62. PubMed ID: 10414877
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial.
Petra Study Team
Lancet; 2002 Apr; 359(9313):1178-86. PubMed ID: 11955535
[TBL] [Abstract][Full Text] [Related]
17. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.
Hammer SM; Squires KE; Hughes MD; Grimes JM; Demeter LM; Currier JS; Eron JJ; Feinberg JE; Balfour HH; Deyton LR; Chodakewitz JA; Fischl MA
N Engl J Med; 1997 Sep; 337(11):725-33. PubMed ID: 9287227
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis.
Bendavid E; Grant P; Talbot A; Owens DK; Zolopa A
AIDS; 2011 Jan; 25(2):211-20. PubMed ID: 21124202
[TBL] [Abstract][Full Text] [Related]
19. Modeling the use of triple combination therapy in five countries: nevirapine, Zidovudine, and Didanosine.
Biddle AK; Simpson KN
Value Health; 2000; 3(3):186-201. PubMed ID: 16464183
[TBL] [Abstract][Full Text] [Related]
20. Costs and benefits of multidrug, multidose antiretroviral therapy for prevention of mother-to-child transmission of HIV in the Dominican Republic.
Schmidt NC; Roman-Pouriet J; Fernandez AD; Beck-Sagué CM; Leonardo-Guerrero J; Nicholas SW
Int J Gynaecol Obstet; 2012 Mar; 116(3):219-22. PubMed ID: 22196992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
